Centessa IPO Presentation Deck

Key Investment Highlights Team: Management team with deep experience developing breakthrough medicines who partner with entrepreneurs offering subject matter expertise 33 Assets: Diversified portfolio of 16 high-conviction uncorrelated programs with potential for biotech-like upside and pharma-like risk profile R&D Model: Combines asset centricity with benefits of scale designed to enable agile and fit-for-purpose research and development Strong Investor Support: Backed by a broad and high-quality group of investors who believe in the vision for our reimagined R&D model Optionality: Evergreen pipeline potentially offers multiple paths to long-term value creation and enhanced shareholder returns CENTESSA 33

View entire presentation